This stock is well into overbought territory.
Shares are set up well for more upside as they begin to put distance on what now appears to be a major double bottom.
ABBV is rising, and the current action could be the start of a strong move higher.
Following the positive action over the last four days, an upside resolution now appears likely. 
The drama between the hedge fund CEO and Herbalife is set for an April 14 screening at the Tribeca Film Festival.
You can hope for a recovery or a bounce or a rally, but hope is not an investment strategy.
The bear market in these stocks will continue until Valeant is resolved.
It doesn't bode well that many officers at the troubled Canadian drugmaker were barred from trading their shares Thursday.
Shares of the pharmaceutical company are headed in the right direction, but the pace of the rally is slowing. 
The biotech company's shares remain range-bound, but a fresh rally appears to be brewing.

Columnist Conversations

Mine and many other reviews of the meeting coming Monday, but the quick highlights to whet your appetite: 1)...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.